Would you summarize the status of the patients in the very first Gleevec clinical trial group?
The patients in our first test group have a very special place in our hearts. They were the pioneers. Many of them are now coming in for their four- and five-year follow-up visits. Most still have normal blood counts. Many have no detectable Philadelphia chromosome. A few patients have relapsed, but in general these patients are doing well, and we continue to follow them quite closely.
